Committee on Market Access - Notification pursuant to the Decision on Notification Procedures for Quantitative Restrictions (G/L/59/Rev.1) - 2024 - 2026 - United Kingdom - Addendum

NOTIFICATION PURSUANT TO THE DECISION ON NOTIFICATION PROCEDURES
FOR QUANTITATIVE RESTRICTIONS (
_G/L/59/Rev.1)

United Kingdom

Addendum

The following communication, dated 31 March 2025, is being circulated at the request of the delegation of the United Kingdom.

 

A.      Notifying Member: United Kingdom

B.      Date of notification: 31 March 2025

C.      First time notification:

      Yes

      No, last notification was made in (doc. symbol): _G/MA/QR/N/GBR/3

D.      Type of notification:

      1.  Complete (i.e. notification of all quantitative restrictions in force)

      2.  Changes to a notification previously made in (_G/MA/QR/N/GBR/3) which are of the following nature:

            2.1   Introduction of new restrictions, as listed in Section 1.

            2.2   Elimination of restrictions, as described in G below.

            2.3   Modification of a previously notified restriction, as described in Section 1.

      3.  Reverse notification of restrictions maintained by (Member):

E.     The notification provides information for the following biennial period (e.g. 2012‑2014): 2024-2026 and relates to restrictions in force as of 31 March 2025

F.      This notification contains information* relating to:

      Section 1:   List of quantitative restrictions that are currently in force.

      Section 2:   Cross-reference to other WTO notifications with information on quantitative restrictions that are currently in force and additional information.

G.      Comments of a general nature, including a description of the elimination of restrictions notified under D.2.2 and the date they ceased to be in force.

1._    The UK is notifying the removal of 19 medicines from the list in critical short supply which are currently subject to export restrictions. These medicines no longer meet the tests set to maintain these measures. These are: Amiodarone, Azithromycin, Aztreonam, Bumetanide, Bupivacaine + Fentanyl, Carbamazepine, Dexamethasone, Heparin, Levomepromazine, Linezolid, Midazolam, Oxycodone, Paracetamol, Permethrin, Prochlorperazine, Quetiapine, Salbutamol, Sodium dihydrogen phosphate anhydrous, and Vinblastine.

2._    The UK is also notifying the addition of 2 medicines to the list in critical short supply.

3._    Insulin isophane human 100units/ml cartridges (3004.31.00) are used in the treatment of diabetes mellitus. They were restricted for export on 20 December 2024 following the supplier discontinuing the product globally. There are currently no alternative medicines that can meet the demand for Insulatard.

4._    Folinic acid (3004.90.00) is used in the treatment of methotrexate toxicity, a chemotherapy drug used to treat various cancers and autoimmune diseases, and for enhancing the effectiveness of 5-fluorouracil in cancer treatment. It was restricted for export on 1 October 2024 due to manufacturing capacity constraints and inability to meet ongoing demand. The UK is also engaging with all Marketing Authorisation Holders to identify any additional stock.

5._    These are temporary measures, in place to relieve critical shortages of medicines necessary for the protection of human health. Restrictions are only applied when critical need cannot be met by alternative measures alone. Measures are reviewed every 6 months, with products removed from the list if there is no longer a critical need. We expect the next review to take place in Spring 2025.

6._    The UK is also notifying the extension of the import and export restrictions of waste by subjecting all e-waste, including non-hazardous e-waste, to the prior informed consent procedure. This implements the Basel Convention E-Waste Amendments which came into force 1 January 2025.

7._    The UK is also notifying the addition of four species to the prohibition of trade in items made of, or containing, ivory. The additional species are common hippopotamus, killer whale, narwhal and sperm whale.

8._    The UK's notification _G/MA/QR/N/GBR/3 included details relating to the Windsor Framework (previously the Northern Ireland Protocol). This notification does not amend those details which continue to apply.

 


Section 1: List of quantitative restrictions that are currently in force

 

QR No.

General description of the restriction

Type of restriction

Tariff line code(s) affected, based on

HS (2022)

Detailed Product Description

WTO Justification and Grounds for Restriction, e.g., Other International Commitments

National legal basis and entry into force

Administration, modification of previously notified measures, and other comments

1

2

3

4

5

6

7

1

#6485

Import and export restrictions of waste: procedures and control regimes for the shipment of waste, depending on the origin, destination and route of the shipment, the type of waste shipped and the type of treatment to be applied to the waste at its destination.

P

CP

P-X

CP-X

Various. For a detailed list of substances, please refer to Annexes III, IV and V of Regulation (EC) No 1013/2006 of the European Parliament and of the Council of 14 June 2006.

Typologies of waste as defined in assimilated Regulation (EC) No 1013/2006 of the European Parliament and of the Council of 14 June 2006 on shipments of waste. For a detailed description of the substances, please refer to Annexes III, IV and V of Regulation (EC) No 1013/2006 of the European Parliament and of the Council of 14 June 2006. 

Basel Convention for the Control of Trans-boundary Movements of Hazardous Waste and their Disposal.

 

OECD Decision on the control of transboundary movements of wastes destined for recovery operations.

 

Article XX(b) GATT

Protection of human, animal or plant life or health.

 

Article XX(g) GATT Conservation of exhaustible natural resources.

Assimilated Regulation (EC) No 1013/2006 of the European Parliament and of the Council of 14 June 2006 on shipments of waste

Available through: 

Regulation (EC) No 1013/2006 of the European Parliament and of the Council of 14 June 2006 on shipments of waste

 

Measure applied from 12.07.2007. 

Administration: Department for Environment Food &   Rural Affairs.

2

#6499

Measures to regulate exports of certain medicaments.

CP-X

Medicines fall under the following commodity codes:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3004.20.00 

 

 

3004.31.00

 

 

 

 

3004.32.00

 

 

 

 

 

3004.39.00

 

 

 

 

3004.50.00

 

 

 

 

3004.90.00

These restrictions apply in certain circumstances to exports of specified medicines which are placed on the UK market for UK patients and needed to protect human health.

 

3. Heading 3004 - Classification

Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale.

 

Other, containing antibiotics 

 

Other, containing hormones or other products of heading 2937

 

Containing corticosteroid hormones, their derivatives or structural analogues.

 

Other, containing hormones or other products of heading 2937 > Other

 

Other, containing vitamins or other products of heading 2936

 

Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale

 

Further detail of these medicines can be found at:

https://www.gov.uk/government/publications/medicines-that-cannot-be-parallel-exported-from-the-uk. 

Article XX(b) GATT Protection of human, animal or plant life or health.

Regulation 43(2) of the Human Medicines Regulations 2012 requiring wholesale dealers to ensure continued supply of medicinal products so that the needs of patients in the UK are met. Further details can be found through: https://www.legislation.gov.uk/uksi/2012/1916/contents/made

The date restrictions came into effect varies by medicine; this is specified for each medicine on the list and available on gov.uk at: 

List of medicines that cannot be exported from the UK or hoarded - GOV.UK

The list of medicines is maintained by the Department of Health & Social Care.

These measures are reviewed regularly, and changes are notified in amendments to this measure.

 

A full change log of previous measures, from October 2019, can be found here under 'See all updates':

https://www.gov.uk/government/publications/medicines-that-cannot-be-parallel-exported-from-the-uk

 

Medicines included on this list meet the following conditions: 

·_        The medicine is required to meet the needs of UK patients.

·_        The medicine is currently in shortage or risk of being in shortage. 

·_        The export of the medicine would contribute to a shortage, or risk of shortage, of that medicine in the UK.

 

Medicines on this list which have been produced to fulfil contracts overseas are not subject to restriction. As such, restrictions only apply to wholesaler dealer license holders that are not the market authorisation holder for a medicine intended for export. The measures are designed to ensure wholesalers fulfil their legal obligations to maintain supply to UK patients.

 

These restrictions are only applied and maintained where alternative measures are not considered sufficient on their own to ensure that UK supply meets demand.

 

A number of exemptions apply to medicines in scope of these restrictions. For example, exports destined for international humanitarian organisations are not covered. A full list of exemptions can be found at: https://www.gov.uk/government/publications/medicines-that-cannot-be-parallel-exported-from-the-uk

 

Requests for exemptions are considered on a case-by-case basis. These can be submitted by a foreign government or government agency, or a wholesaler on their behalf at restrictedmedicines@dhsc.gov.uk

 

Further information on these measures is available here: https://www.gov.uk/guidance/parallel-export-and-hoarding-of-restricted-medicines

 

It is the responsibility of the wholesaler to ensure any exports are made or withheld in compliance with these restrictions. Failure to comply with these restrictions may lead to regulatory action by the Medicines and Healthcare products Regulatory Authority (MHRA) against the wholesale dealer's licence.

 

There are no additional steps or declarations required from a customs perspective.

3

#9001

Extension of the prohibition which applies to the trade in items made of, or containing, ivory. This prohibition applies regardless of an item’s age, unless it falls within one of the legally defined exemptions. The prohibition has been extended to include items made of, or containing, ivory from four additional species: common hippopotamus, killer whale, narwhal and sperm whale.

CP

NAL

See Annex below.

List of prohibited items under the Ivory Act (2018):

https://www.legislation.gov.uk/ukpga/2018/30/contents/enacted

 

Additional items prohibited under Part 2 of The Ivory Act 2018 (Meaning of "Ivory" and Miscellaneous Amendments) Regulations 2025:

https://www.legislation.gov.uk/uksi/2025/9/part/2/made

Convention on International Trade in Endangered Species of Wild Fauna and Flora 

(CITES).

 

Article XX(a) GATT Protection of public morals.

 

Article XX(b) GATT 

Protection of human, animal or plant life or health.

 

Article XX(g) of the GATT Conservation of exhaustible natural resources.

Ivory Act (2018), entered into force 06.06.2022.

 

Available through: https://www.legislation.gov.uk/ukpga/2018/30/contents/enacted

 

The Ivory Act 2018 (Meaning of “Ivory” and Miscellaneous Amendments) Regulations 2025 entered into force 28.01.2025

 

Available through:

https://www.legislation.gov.uk/uksi/2025/9/part/2/made

Administration: Department for Environment, Food & Rural Affairs.

 

Regulator: Animal and Plant Health Agency.

 

Guidance:

https://www.gov.uk/guidance/dealing-in-items-containing-ivory-or-made-of-ivory

 


 

Annex

List of tariff lines covered by QRs No. 3

QRNo.

Tariff line code(s) affected, based on

HS (2022)

3

#9001

Items made of or containing ivory

 

0507100000, 4420, 442011, 4420111010, 4420111090, 4420119000, 442019, 4420901000, 4420909191, 4420909199, 4420909910, 4420909990, 7113, 7113110000, 7113190000, 7113200000, 7114, 7114110000, 7114190000, 7114200000, 7115, 7116, 7116100000, 8211, 8211100000, 8211910000, 8211920000, 8215, 821510, 8215102000, 8215103000, 821520, 8215201000, 8215209000, 9201, 920110, 9201101000, 9201109000, 9201200000,  9201900000, 9202, 920210, 9202101000, 9202109000, 920290, 9202903000, 9202908000, 9205, 9205100000, 920590, 9205901000, 9205903000, 9205905000, 9205909000, 9206, 9209, 9209300000, 9209910000, 9209920000, 9209940000, 920999, 9209992000, 9209997000, 9403, 940340, 94034010, 9403401010, 9403401090, 94034090, 9403409010, 9403409090, 9403500000, 940360, 9403601000, 9403603000, 9403609000, 9504, 9504200000, 9504908000, 9601, 960110, 9601100010, 9601100090, 9701, 970121, 9701210000, 9701220000, 9701290000, 9703, 9703100000, 9703900000,  9706, 9706100000, 9706900000

 

__________



* In English only.